文献速递糖尿病

呼吁为妊娠期1型糖尿病研发自动胰岛素输注系统

Automated Insulin Delivery for Pregnancy With Type 1 Diabetes: A Call to Action.
PubMed 文献 · Diabetes Care · 2026-09-24

本文指出妊娠期1型糖尿病需强化胰岛素治疗以达到低于非妊娠期的血糖目标,但现有自动胰岛素输注(AID)系统未针对妊娠设计且多未获批用于妊娠,临床试验广泛排除孕妇导致数据极度有限,呼吁将孕妇纳入AID临床试验并设计满足妊娠需求的系统。

要点

  • 妊娠期血糖目标低于非妊娠期,现有AID系统未针对妊娠设计且多数未获批。
  • 临床试验广泛排除孕妇,导致AID在妊娠期使用的数据极度有限。
  • 呼吁将孕妇纳入AID试验、设计妊娠专用系统并支持现有系统真实世界研究。

核心结论

  • 应让妊娠期1型糖尿病女性参与AID临床试验,并设计满足妊娠独特血糖管理需求的AID系统。

研究设计与样本

  • 本文为呼吁性文章,未报告系统检索方法或样本量。

主要发现

  • 妊娠期血糖目标低于非妊娠期,极难达成,给孕妇带来显著负担和心理困扰。
  • 美国FDA批准的AID系统未针对妊娠血糖目标设计,且多数未标注用于妊娠。
  • 临床试验广泛排除孕妇,导致AID系统在妊娠期使用的数据极度有限。
  • 多数设备在CGM传感器值处于胎儿健康最佳范围时减少胰岛素输注。

关键数值与推荐

  • AID现为1型糖尿病推荐的胰岛素输注模式。
  • 妊娠期血糖目标低于非妊娠期。

临床怎么用

  • 应支持现有获批AID系统在妊娠期的真实世界研究,同时等待妊娠专用创新。
  • 应推动将孕妇纳入新AID技术的临床试验。

局限性

  • 本文为呼吁性文章,未提供原始研究数据或系统评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 1 diabetes (T1D) requires intensive glycemic management in pregnancy with insulin to achieve pregnancy-specific glycemic targets and avoid serious maternal and perinatal morbidity. Glycemic targets for pregnancy, which are lower than those outside pregnancy, are extremely challenging to achieve, resulting in considerable burden and psychosocial distress for pregnant women living with T1D. While automated insulin delivery (AID) is now the recommended mode of insulin delivery for T1D, pregnant women with T1D have been left behind. AID systems approved by the U.S. Food and Drug Administration for use in the U.S. are not designed to meet pregnancy glycemic targets, and most are not labeled for pregnancy. Broad exclusion of pregnant participants from clinical trials, including those of AID systems, has resulted in extremely limited data to guide the use of these devices in pregnancy. Furthermore, for most devices insulin delivery is reduced when continuous glucose monitoring (CGM) sensor values are in the optimal range for fetal well-being. We call on stakeholders to deliver AID systems that meet the needs of pregnant women with T1D so that they can use AID at a time in life when they stand to benefit the most. Specifically, we should include pregnant women in clinical trials of new AID technologies, design AID systems that can meet the unique glycemic management challenges of pregnancy, and support real-world studies of currently approved AID systems while we await pregnancy-specific innovations.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Automated Insulin Delivery for Pregnancy With Type 1 Diabetes: A Call to Action. Diabetes Care. 2026. PMID: 42782208. doi:10.2337/dci26-0045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。